NJ ACTS Special Populations Seminar with Princeton’s Dr. Daniel A. Notterman

The New Jersey Alliance for Clinical and Translational Science and IFH’s Center for Health Services Research presents:

NJ ACTS Special Populations Seminar

Daniel A. Notterman, MA, MD, Professor & Vice Dean of Biomedical & Clinical Research, Princeton University

“Clinical, Epidemiological, and Molecular Insights from the Future of Families Cardiovascular Health Study”

As the original cohort of the Future of Families and Child Wellbeing Study enters early adulthood, this lecture presents findings from a population-based sample of 2,000 young adults examining how childhood adversity, risk behaviors, and social and demographic factors shape early cardiovascular health. We report associations between these exposures and multiple cardiovascular outcomes, including the American Heart Association’s Life’s Essential 8 cardiovascular health score, carotid intima–media thickness, and related clinical and laboratory markers of atherosclerosis. At age 23, specific risk behaviors were linked to poorer cardiovascular health and increased CIMT, indicating early vascular disease. Longitudinal DNA methylation analyses at ages 9, 15, and 23 reveal that many of these abnormalities are associated with gene-specific methylation changes detectable by age 9, which persist through adolescence into adulthood, suggesting the emergence of an adverse epigenetic phenotype well before puberty.

Register to Attend: https://go.rutgers.edu/zdvwbsu

Daniel is a pediatrician by clinical training and a biologist whose research examines interactions between genetic variants and environmental signals in the developing behavioral, cognitive and emotional phenotype of the child. He wishes to understand the interactions between specific genetic variants, environmental signals, and resulting behavioral and health outcomes. As Vice Dean for Biomedical and Clinical Research, Daniel supports the Office of the Dean for Research in facilitating Princeton’s growing portfolio of clinical research and other research that involves the use of biomaterials or biomedical health data obtained from human subjects. In this role, he advises the Dean for Research, the Institutional Review Board (IRB) chair, and the Research Integrity & Assurance (RIA) director and staff on facilitating compliant clinical research.